Durban: South African pharmaceutical company Aspen Pharmacare said it has entered into an agreement with ‘Johnson & Johnson’ (J&J) for the technical transfer and proposed commercial manufacturing of their Covid-19 vaccine candidate.
The vaccine candidate, Ad26.COV2-S is currently undergoing clinical trials.
Aspen Pharmacare on Monday said it will perform formulation, filling and secondary packaging of the vaccine for supply to Johnson & Johnson.
This agreement is still subject to the successful completion of the relevant technology transfer activities and finalisation of certain commercial manufacturing terms.
“We have been selected as a vaccine partner by Johnson & Johnson and this project will receive priority focus,” said Stephen Saad, Aspen Group Chief Executive.
“We are particularly pleased to be given the opportunity of providing assistance for patients in need across the…
